Arrowstreet Capital
CALA

Arrowstreet Capital’s Calithera Biosciences, Inc CALA Stock Holding History

Arrowstreet Capital’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-946
Closed -$93K – 2649
2020
Q4 		$93K Buy
+946
New +$82.9K ﹤0.01% 2227

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital's CALA Position: Q1 2021 in Review

Arrowstreet Capital sold out of Calithera Biosciences, Inc (CALA) in Q1 2021, closing a stake of 946 shares — an estimated $93K sold.

Arrowstreet Capital first reported a position in CALA in Q4 2020 and held it in 1 quarter. The position peaked at $93K in Q4 2020. 100 funds tracked by Wall St. Rank hold CALA as of Q1 2021.

  • Arrowstreet Capital reported no remaining Calithera Biosciences, Inc position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 946 Calithera Biosciences, Inc shares in Q1 2021, an estimated $93K.
  • Arrowstreet Capital first reported a position in Calithera Biosciences, Inc in Q4 2020 and held it in 1 quarter.
  • Arrowstreet Capital's Calithera Biosciences, Inc position peaked at $93K in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.